Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina.
Centro de Investigaciones Epidemiológicas y Salud Pública (CIESP-IECS), CONICET, Buenos Aires, Argentina.
J Antimicrob Chemother. 2023 Jun 1;78(6):1322-1336. doi: 10.1093/jac/dkad071.
Detailed information is needed on the dynamic pattern of antimicrobial resistance (AMR) in Neisseria gonorrhoeae in Latin America and the Caribbean (LAC).
To conduct a systematic review of AMR in N. gonorrhoeae in LAC.
Electronic searches without language restrictions were conducted in PubMed, Embase, Cochrane Library, EconLIT, Cumulative Index of Nursing and Allied Health Literature, Centre for Reviews and Dissemination, and Latin American and Caribbean Literature in Health Sciences. Studies were eligible if published between 1 January 2011 and 13 February 2021, conducted in any LAC country (regardless of age, sex and population) and measured frequency and/or patterns of AMR to any antimicrobial in N. gonorrhoeae. The WHO Global Gonococcal Antimicrobial Surveillance Programme (WHO-GASP) for LAC countries and Latin American AMR SurveillanceNetwork databases were searched. AMR study quality was evaluated according to WHO recommendations.
AMR data for 38, 417 isolates collected in 1990-2018 were included from 31 publications, reporting data from Argentina, Brazil, Colombia, Peru, Uruguay, Venezuela and WHO-GASP. Resistance to extended-spectrum cephalosporins was infrequent (0.09%-8.5%). Resistance to azithromycin was up to 32% in the published studies and up to 61% in WHO-GASP. Resistance to penicillin, tetracycline and ciprofloxacin was high (17.6%-98%, 20.7%-90% and 5.9%-89%, respectively). Resistance to gentamicin was not reported, and resistance to spectinomycin was reported in one study.
This review provides data on resistance to azithromycin, potentially important given its use as first-line empirical treatment, and indicates the need for improved surveillance of gonococcal AMR in LAC. Trial registration: Registered in PROSPERO, CRD42021253342.
需要详细了解拉丁美洲和加勒比地区(LAC)淋病奈瑟菌的抗生素耐药性(AMR)动态模式。
对 LAC 淋病奈瑟菌的 AMR 进行系统评价。
对 PubMed、Embase、Cochrane 图书馆、EconLIT、护理学及相关健康科学累积索引、中心评价与传播、拉丁美洲和加勒比卫生科学文献进行了无语言限制的电子检索。如果研究在 2011 年 1 月 1 日至 2021 年 2 月 13 日之间发表,在任何 LAC 国家(无论年龄、性别和人群如何)进行,并测量了任何抗菌药物对淋病奈瑟菌的 AMR 频率和/或模式,则研究合格。还对拉丁美洲和加勒比国家的世界卫生组织全球淋球菌抗菌药物监测计划(WHO-GASP)和拉丁美洲 AMR 监测网络数据库进行了搜索。根据世卫组织的建议评估了 AMR 研究的质量。
从 31 篇出版物中纳入了 1990 年至 2018 年期间收集的 38417 株分离株的 AMR 数据,这些出版物报告了来自阿根廷、巴西、哥伦比亚、秘鲁、乌拉圭、委内瑞拉和 WHO-GASP 的数据。对扩展型头孢菌素的耐药性罕见(0.09%-8.5%)。已发表的研究中,阿奇霉素的耐药率高达 32%,而 WHO-GASP 中的耐药率高达 61%。青霉素、四环素和环丙沙星的耐药率很高(分别为 17.6%-98%、20.7%-90%和 5.9%-89%)。未报告庆大霉素耐药性,仅有一项研究报告大观霉素耐药性。
本综述提供了有关阿奇霉素耐药性的数据,鉴于其作为一线经验性治疗的应用,这一点非常重要,并表明需要改善 LAC 淋病奈瑟菌 AMR 的监测。试验注册:在 PROSPERO 注册,CRD42021253342。